4 Min Read FRANKFURT/COPENHAGEN (Reuters) - Germany’s Qiagen, a leading genetic testing supplier, on Thursday warned against re-engineering standard tests to monitor for new variants of the coronavirus, saying the more onerous decoding of the entire viral genome was the best method. FILE PHOTO: Illustration of products are pictured from Qiagen, the diagnostics company which has agreed an $11.5 billion takeover deal with U.S-based Thermo Fisher in this picture illustration obtained by Reuters March 3, 2020. Qiagen/Handout via REUTERS Scientists believe more contagious variants have fuelled a surge in global coronavirus cases that have exceeded 90 million, and nations are racing to procure vaccines and tighten lockdown measures.